Stargardt disease

Stargardt disease (STGD1) is the most frequent hereditary macular dystrophy. It is characterized by a progressive loss of central vision and is associated, in most cases, with biallelic variants in the ABCA4 gene. These alterations favor the accumulation of toxic retinoid compounds in the retina, damaging the retinal pigment epithelium and photoreceptors.

The ABCA4 gene encodes a transporter protein located in the outer segments of photoreceptors in the retina, both cones and rods. Its function is to remove derivatives from the visual cycle, such as N-retinylidene phosphatidylethanolamine, so that they can be properly processed and eliminated.

When pathogenic variants exist in ABCA4, this transport function is reduced or lost. As a consequence, bisretinoids and lipofuscin accumulate in the retinal pigment epithelium, especially in the macular region, leading to progressive damage of photoreceptors and loss of central vision. ABCA4-associated disease usually follows an autosomal recessive pattern, meaning an affected person typically inherits one pathogenic variant from each parent. Stargardt-like phenotypes can be caused by other genes and present with other inheritance patterns. Stargardt disease is the most common inherited macular dystrophy, with an approximate prevalence of 1 in 8,000 to 10,000 people.

Symptoms

Onset usually occurs in late childhood, adolescence, or young adulthood, although there are later onset forms. The main symptom is progressive loss of central visual acuity, which may be accompanied by a central scotoma, difficulty reading or recognizing faces, altered color perception, and slow adaptation to darkness. Peripheral vision is usually preserved for a long time, although it may be affected in stages.

Disease management

Currently, there is no cure or approved pharmacological treatment that definitively stops the progression of Stargardt disease. Management focuses on specialized ophthalmological monitoring, low vision aids, and measures to reduce retinal stress, such as avoiding intense sun exposure and using UV-protective glasses. High-dose vitamin A or beta-carotene supplements are recommended to be avoided, unless medically indicated. There are ongoing trials with visual cycle modulators, gene therapies, oligonucleotides, and cell therapies.

Genes analyzed

ABCA4 U
U Ultra Whole Genome Sequencing 30x

Bibliography

Cornelis SS, Runhart EH, Bauwens M, et al. Personalized genetic counseling for Stargardt disease: Offspring risk estimates based on variant severity. Am J Hum Genet. 2022 Mar 3;109(3):498-507.

Dayma K, Rajanala K, Upadhyay A. Stargardt's Disease: Molecular Pathogenesis and Current Therapeutic Landscape. Int J Mol Sci. 2025 Jul 21;26(14):7006.

Wang L, Shah SM, Mangwani-Mordani S, et al. Updates on Emerging Interventions for Autosomal Recessive ABCA4-Associated Stargardt Disease. J Clin Med. 2023 Sep 27;12(19):6229.

Molday RS, Garces FA, Scortecci JF, et al. Structure and function of ABCA4 and its role in the visual cycle and Stargardt macular degeneration. Prog Retin Eye Res. 2022 Jul;89:101036.

What do your genes say about you? Start your journey today.

Get a special 5% discount on your first kit.

Haven't you taken our DNA test yet?

Get your genetic test and discover what your DNA says about you.

pack
Starter DNA test
The best option to get started

Ancestry service, Traits and Wellness

Buy
pack
DNA test Advanced DNA test
Know your DNA in depth

Health, Ancestry service, Traits and Wellness

Buy
pack
Genetic analysisUltra
Whole Genome Sequencing 30x

Health, Ancestrality, Traits and Wellness

includes three months of tellmeGen+

Buy

Important information and limitations

Europe
Austria
Belgium
Czech Republic
Denmark
Finland
Germany
Hungary
Ireland
Italy
Netherlands
Norway
Poland
Portugal
Romania
Spain
Sweden
Switzerland
United Kingdom
Asia
Kazakhstan
Saudi Arabia
UAE
America
Brazil
Canada
Chile
Colombia
Mexico
Panama
Peru
United States
Oceania
Australia
The Best Prices of the Year! Only until November 27 Use our coupon BLACK15
Buy